MARKET NEWS

 

Schreiner MediPharm & Plas-Tech Engineering Collaborate to Offer Full-Service First-Opening Indication for Prefilled Syringes
Processa Pharmaceuticals Enters Licensing & Development Agreement With Ocuphire Pharma
Onconova Therapeutics Announces Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined With Immune Checkpoint Blockade
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-Based BNT111 in Patients With Advanced Melanoma
Nemera Breaks Ground in Brazil Through Milfra Acquisition
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Emergent CDMO is dedicated to helping pharma and biotech innovators bring lifesaving therapies to patients from around the world. Our nine development and manufacturing sites in North America and Europe can support early to late stage production of biotherapeutics and vaccines. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced CDMO team is ready to serve as your trusted guide from molecule to market. Click here for more.

  EXCLUSIVE ONLINE CONTENT

uniQure to Acquire Corlieve Therapeutics & Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

uniQure to Acquire Corlieve Therapeutics & Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

uniQure N.V. recently announced it has entered into a definitive agreement to acquire Corlieve Therapeutics and its lead program, which will be known as….

vTv Therapeutics & Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development & Commercialization of Cancer Treatment

vTv Therapeutics & Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development & Commercialization of Cancer Treatment

vTv Therapeutics Inc. and Cantex Pharmaceuticals, Inc. recently announced they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to….

Vectura Signs Preclinical Development Agreement With Incannex 

Vectura Signs Preclinical Development Agreement With Incannex 

Vectura Group plc recently announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide preclinical development services for….

Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration With Site Sponsors

Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration With Site Sponsors

Syneos Health recently expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for….

Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy

Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 7 – Prefilled Syringes
July 14 – Parenteral Contract Manufacturing